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treatment, and persistently increased plasma fi‑
brin D ‑dimer levels.4 It is well known that VTE 
provoked by transient risk factors is associated 
with lower recurrence risk compared with an un‑
provoked VTE, and in most cases a 3 ‑month an‑
ticoagulant treatment is recommended.5 Fur‑
thermore, elimination of exposure to immobi‑
lization, surgery, and trauma in patients with a 
first unprovoked VTE episode does not result in 
a decreased risk of recurrence.6
Direct oral anticoagulants are now commonly 
used in acute VTE treatment and secondary pre‑
vention of recurrences.7 Compared with VKAs, 
treatment with DOACs in patients with VTE is 
associated with a 39% reduction in bleeding risk 
INTRODUCTION Venous thromboembolism 
(VTE), including deep vein thrombosis (DVT) 
and pulmonary embolism (PE), afflicts over 1 mil‑
lion people in Europe annually.1 The 1 ‑year in‑
cidence of recurrent VTE is approximately 2% 
among patients receiving direct oral anticoagu‑
lants (DOACs) or vitamin K antagonists (VKAs),2 
and rises to 11% at 1 year and 30% at 5 years 
among individuals following unprovoked VTE 
after cessation of anticoagulation.3 The main es‑
tablished risk factors predisposing to VTE re‑
currence include older age, male sex, high body 
mass index (BMI), active cancer, unprovoked 
VTE, proximal DVT or PE, antiphospholipid an‑
tibody syndrome, short duration of anticoagulant 
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ABSTRACT
INTRODUCTION Denser fibrin structure and impaired fibrinolysis reported in patients following venous 
thromboembolism (VTE) can predict recurrent VTE after cessation of anticoagulation.
OBJECTIVES The aim of the study was to investigate whether the properties of fibrin clot may be useful 
in predicting adverse events in patients with VTE receiving rivaroxaban.
PATIENTS AND METHODS In 132 patients with VTE treated with rivaroxaban for 8 weeks or longer, we 
determined plasma clot permeability (Ks) and clot lysis time (CLT) in blood samples collected 2 to 28 
hours after rivaroxaban intake (20 mg/d). The primary endpoint was a composite of major and clinically 
relevant nonmajor bleeding, while the secondary endpoint was recurrent symptomatic VTE.
RESULTS During a median follow ‑up of 32 months, the annual rates of primary and secondary endpoints 
were 3.6% and 2.7%, respectively. There were no differences in Ks and CLT between individuals who 
experienced the primary endpoint and the remainder. Patients with recurrent VTE had lower baseline Ks 
(–26.7%) and prolonged CLT (+20.8%) on rivaroxaban, without differences in rivaroxaban concentrations 
at the time of blood collection. After adjustment for confounding factors, Ks was the only predictor of 
VTE recurrence on rivaroxaban (odds ratio, 0.23; 95% CI, 0.06–0.94).
CONCLUSIONS Our study suggests that Ks assessed on rivaroxaban may provide prognostic information 
about the risk of recurrent VTE in anticoagulated patients.
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criteria were: age below 18 or above 65 years, signs 
of acute infection, acute coronary syndrome or 
ischemic stroke within the previous 3 months, 
indications for anticoagulant therapy other than 
VTE, known malignancy, chronic kidney disease 
stage 4 or 5, indications for anticoagulation oth‑
er than VTE (eg, atrial fibrillation), self ‑declared 
interruption in rivaroxaban use longer than 48 
hours within the previous 6 weeks, major sur‑
gery or trauma within the preceding 3 months. 
All enrolled patients declared regular rivaroxa‑
ban intake.
The diagnosis of DVT was established by a posi‑
tive finding on Doppler vein ultrasound (visualiza‑
tion of an intraluminal thrombus in calf, poplite‑
al, femoral, or iliac veins). The diagnosis of PE was 
based on the presence of typical symptoms and 
positive results on high‑resolution spiral comput‑
ed tomography (CT). The diagnosis of thrombosis 
at unusual sites (cerebral venous sinus thrombo‑
sis, portal vein thrombosis) were based on clin‑
ical symptoms combined with abnormalities on 
CT angiography, magnetic resonance imaging, or 
magnetic resonance angiography.
Unprovoked VTE was defined as VTE in a pa‑
tient with no history of cancer, surgery or trau‑
ma, plaster cast, immobilization, or hospitaliza‑
tion in the past 3 months, use of oral contracep‑
tives or hormone replacement therapy, and preg‑
nancy or delivery in the past 3 months.
Data concerning demographic characteristics, 
risk factors for VTE, comorbidities, and current 
treatment were collected from all participants 
using a standardized questionnaire. Family his‑
tory of VTE was defined as a confirmed VTE epi‑
sode in a first ‑degree relative. Arterial hyperten‑
sion was established as systolic blood pressure 
of 140 mm Hg and /or diastolic blood pressure 
90 mm Hg and /or treatment with antihyperten‑
sive drugs. Diabetes mellitus was defined accord‑
ing to the American Diabetic Association crite‑
ria. Obesity was defined as a BMI of 30 kg/m2 or 
greater. Coronary heart disease was established 
based on a documented history of myocardial in‑
farction or a positive result on exercise stress test, 
or gated single ‑photon emission CT (SPECT) with 
technetium (99mTc) sestamibi, or coronary angi‑
ography. Hypercholesterolemia was defined as 
a total cholesterol level of 5.2 mmol/l or higher, 
or a low ‑density lipoprotein cholesterol level of 
3 mmol/l or higher, and hypertriglyceridemia as 
a triglyceride concentration above 1.7 mmol/l. Hy‑
perhomocysteinemia was defined as a plasma ho‑
mocysteine concentration of 15 µmol/l or higher.
The ethical committee of Jagiellonian Univer‑
sity approved the study. All participants gave in‑
formed consent in accordance with the Declara‑
tion of Helsinki.
Laboratory tests Blood samples were drawn from 
an antecubital vein with minimal stasis using 
atraumatic venipuncture between 09:00 AM and 
12:00 PM. Rivaroxaban was taken 2 to 28 hours 
prior to blood collection based on the patient’ 
and 64% reduction in mortality rates with simi‑
lar efficacy.8 Rivaroxaban is the most commonly 
used DOAC among VTE patients in the majority 
of European countries.9 The EINSTEIN ‑PE (Oral 
Direct Factor Xa Inhibitor Rivaroxaban in Patients 
With Acute Symptomatic Pulmonary Embolism) 
and EINSTEIN ‑DVT (Oral Direct Factor Xa Inhib‑
itor Rivaroxaban in Patients With Acute Symp‑
tomatic Deep Vein Thrombosis) studies showed 
that the risk of VTE recurrence is 2.1% during 
a 3‑ to 12‑month rivaroxaban treatment in pa‑
tients with DVT or PE, while the risk of major or 
clinically relevant nonmajor bleeding is 8.1% and 
10.3% in patients with DVT and PE, respective‑
ly.10,11 The risk of bleeding on rivaroxaban is in‑
creased by the following factors: older age, prior 
bleeding, malignancy ‑associated VTE, renal and 
liver impairment, bleeding disorders, and con‑
current use of antiplatelet drugs, while previous 
unprovoked VTE, active cancer, proximal DVT 
or PE, and elevated plasma D ‑dimer levels have 
been reported as risk factors of VTE recurrences 
on rivaroxaban.12,13
Fibrin, a major component of venous thrombi, 
forms highly variable networks of different den‑
sity and lysability governed by genetic and envi‑
ronmental factors.14 Denser fibrin clots display‑
ing impaired lysability have been shown to be as‑
sociated with an increased risk of VTE and its re‑
currence.15,16 It is known that effective fibrino‑
lysis is essential for fibrin clot degradation and, 
subsequently, maintaining vessel patency.17 In vi‑
tro studies have demonstrated that rivaroxaban 
prolongs the initiation phase of thrombin gen‑
eration, reduces the maximum concentration of 
thrombin generated, and renders the fibrin struc‑
ture more permeable and susceptible to fibrino‑
lysis.18,19 Janion ‑Sadowska et al20 have shown re‑
cently that rivaroxaban at peak plasma concentra‑
tions improves plasma clot permeability and clot 
lysis time (CLT) in patients with previous VTE by 
37% and 25%, respectively. The prothrombotic 
clot phenotype, reflected by clot permeability, be‑
ing the main measure of clot structure, has been 
shown to be an independent predictor of throm‑
boembolic events and major bleeding in patients 
with atrial fibrillation receiving VKA.21,22
To the best of our knowledge, it is unknown 
whether plasma fibrin clot properties assessed in 
patients on rivaroxaban during ambulatory vis‑
its may be useful in predicting thromboembol‑
ic and /or bleeding episodes in those after VTE. 
Therefore, our aim was to evaluate a predictive 
value of clot permeability and CLT in relation to 
plasma rivaroxaban concentrations in a cohort 
of patients with VTE.
PATIENTS AND METHODS Patients We recruited 
132 consecutive adult patients with documented 
DVT and /or PE who were treated with rivarox‑
aban (20 mg/d) and were referred to our Center 
for Coagulation Disorders for clinical or labora‑
tory workup. Patients were eligible if at least 8 
weeks elapsed since the index event. The exclusion 
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the clear ‑to ‑maximum ‑turbid transition, which 
represents clot formation, to the midpoint of 
the maximum ‑turbid ‑to ‑clear transition, which 
represents clot degradation.29
Follow ‑up The follow ‑up started on the day 
of blood collection and was carried out on 
the 6 ‑month basis (a visit at the center or a tele‑
phone contact). The primary endpoint was ma‑
jor bleeding or clinically relevant nonmajor bleed‑
ing defined according to the International So‑
ciety on Thrombosis and Hemostasis criteria.30 
The secondary endpoint was recurrent symptom‑
atic VTE defined as a subsequent VTE episode 
during follow ‑up, using the same criteria as at the 
index event with imaging in each case. In cases of 
a suspected recurrence of DVT in the same leg as 
the index event, noncompressibility of a previous‑
ly compressible venous segment or an increase of 
at least 4 mm in the residual diameters were ap‑
plied to confirm the diagnosis. Patients with sus‑
pected PE underwent spiral CT, followed by pul‑
monary angiography in the case of a high clinical 
probability despite normal CT scans. In patients 
with signs or symptoms suggestive of DVT, col‑
or duplex sonography was performed.
Statistical analysis The study was powered to 
have a 90% chance of detecting a 10% difference 
in CLT using an α value of 0.05, based on the CLT 
values presented elsewhere.31 To demonstrate 
such a difference or greater, 34 patients were re‑
quired in each group. In turn, to demonstrate 
such a difference or greater in Ks using an α val‑
ue of 0.05, at least 31 patients were required in 
each group.15
Categorical variables are presented as num‑
bers and percentages. Continuous variables are 
expressed as mean (SD) or median and interquar‑
tile range (IQR), as appropriate. Normality was 
assessed by the Shapiro–Wilk test. Equality of 
variances was assessed using the Levene test. 
The continuous variables were compared between 
2 groups using the t test for nonrelated groups 
for mean values and the Mann–Whitney test for 
median values. Categorical variables were ana‑
lyzed using the χ2 test or the Fisher exact test, 
as appropriate. The Pearson correlation coeffi‑
cient or Spearman rank correlation coefficient 
were calculated to assess the linear correlations 
between variables with normal or nonnormal dis‑
tribution, respectively. Prognostic values of Ks 
and CLT were analyzed with logistic regression 
models (univariable and multivariable; the re‑
sults were presented as odds ratios (ORs) and 
their 95% CIs. The univariate models were built 
to assess the crude odds ratios for the relation 
between factors and the outcome. Multivariable 
models were adjusted for potential confound‑
ers including age, sex, BMI, fibrinogen, unpro‑
voked VTE status, and plasma rivaroxaban con‑
centrations. A P value of less than 0.05 was con‑
sidered significant. All calculations were done 
declaration. Lipid profiles, complete blood count, 
glucose, and creatinine were assayed by routine 
laboratory techniques. Fibrinogen was deter‑
mined using the Clauss assay. High ‑sensitivity 
C ‑reactive protein was measured by immuno‑
turbidimetry (Roche Diagnostics, Mannheim, 
Germany). Plasma D ‑dimer was measured with 
the Innovance D ‑dimer assay (Siemens, Marburg, 
Germany).
All patients were tested for thrombophil‑
ia, including antithrombin, protein C, or pro‑
tein  S deficiency, factor V Leiden, and pro‑
thrombin G20210A polymorphism, as described 
elsewhere.23
Rivaroxaban concentrations were measured by 
the anti ‑Xa chromogenic assay, Biophen DiXaI 
(Hyphen Biomed, Neuville ‑sur ‑Oise, France), ac‑
cording to the manufacturer’s instructions.24 We 
arbitrarily used the cutoff vaule of 30 µg/l25 and 
prespecified the group with low rivaroxaban con‑
centrations (≤30 μg/l) and the group with high ri‑
varoxaban concentrations (>30 μg/l).
Fibrin clot evaluation To evaluate clot properties, 
venous blood samples (volume ‑to ‑volume ratio, 
3.2% trisodium citrate at an anticoagulant ‑to‑
‑blood ratio of 9 to 1) were centrifuged at 2000 × g 
for 10 minutes within 30 minutes of the draw, 
and the supernatant was aliquoted and stored 
at –80°C until analysis. All measurements were 
performed by technicians blinded to the origin 
of the samples. Intra ‑assay and interassay co‑
efficients of variation were approximately 7%.
Fibrin clot permeability Clot permeability, indi‑
cating the pore size in fiber networks, is propor‑
tional to a volume of buffer percolating through 
a clot under a specific hydrostatic pressure and 
was determined using a pressure ‑driven system 
as described elsewhere.17 Briefly, calcium chloride 
(20 mmol/l) and human thrombin (1 U/ml, Cal‑
biochem) were added to 120 µl of citrated plas‑
ma. Tubes which contained the clots were joined 
with a reservoir of Tris ‑buffered saline (0.1 mol/l 
NaCl, 0.01 mol/l Tris, pH 7.5). The volume flow‑
ing for 60 minutes through the gels was assessed. 
Plasma clot permeability was expressed as a per‑
meation coefficient (Ks) and was calculated from 
the equation: Ks = (Q × L × µ) / (t × A × Δp), where Q 
is the flow rate in time; L, the length of a fibrin gel; 
µ, the viscosity of liquid (in poise); A, the cross‑
‑sectional area (in cm2), Δp, a differential pres‑
sure (in dyne/cm2), and t the percolating time.26
Clot lysis time To assess CLT, we used a modified 
lysis assay introduced by Lisman et al.27,28 Brief‑
ly, citrated plasma was mixed with 16 mmol/l 
calcium chloride, 10 000 pg/ml human tissue 
factor (Innovin, Siemens) with a final concen‑
tration of 0.6 pmol/l, 12 µmol/l phospholipid 
vesicles, and 32 ng/ml rtPA (Boehringer Ingel‑
heim, Ingelheim, Germany). The turbidity was 
measured at 405 nm at 37°C. Clot lysis time 
was defined as the time from the midpoint of 
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with cerebral venous sinus thrombosis or portal 
vein thrombosis. A total of 72 patients (54.5%) 
experienced unprovoked VTE. The time from 
the last VTE to enrollment ranged between 2 and 
65 months (median [IQR], 32 [19‑40]).
Based on rivaroxaban concentrations at the 
time of blood collection, 2 subgroups were dis‑
tinguished: with high rivaroxaban concentrations 
(n = 65, 49.2%) and with low rivaroxaban con‑
centrations (n = 67, 50.8%), with a median (IQR) 
drug concentration of 103 (47–195) µg/l and 3 
(0–13) µg/l, respectively (TABLE 1). The mean time 
from the last rivaroxaban administration was 12 
(4–20) hours and 25 (22–27) hours, respective‑
ly. As expected, the plasma rivaroxaban concen‑
tration was inversely correlated with time from 
its last intake (r = –0.66, P <0.01). There were 
no intergroup differences with regard to demo‑
graphic variables, VTE risk factors, and comor‑
bidities (TABLE 1). In terms of routine laboratory 
tests, the group with low rivaroxaban concentra‑
tions had higher D ‑dimer concentrations and low‑
er platelet count, without other intergroup dif‑
ferences, including fibrinogen (TABLE 1).
The analysis of thrombophilias yielded simi‑
lar frequencies in both groups (TABLE 1). The pro‑
thrombin 20210A mutation tended to occur more 
often in the group with high rivaroxaban levels, 
although the difference did not reach the level 
of significance.
Fibrin clot properties Plasma rivaroxaban concen‑
trations were strongly positively correlated with 
Ks in the whole group (r = 0.8, P = 0.01) (FIGURE 1A). 
There was no correlation between plasma rivar‑
oxaban concentrations and Ks in the group with 
low rivaroxaban concentrations (r = 0.18, P = 0.13) 
(FIGURE 1B), whereas in the group with high rivarox‑
aban concentrations, there was a positive correla‑
tion between Ks and drug concentrations (r = 0.85, 
P = 0.01) (FIGURE 1C). Patients in the low rivaroxaban 
group formed denser clots (mean [SD] Ks, 6.37 [1.6] 
10 –9 cm2 vs 9.04 [2] 10 –9 cm2; P <0.001) (FIGURE 1D).
Clot lysis time correlated inversely with riva‑
roxaban concentrations in the whole group (r = 
–0.85, P = 0.01) (FIGURE 2A), and both in the group 
with low rivaroxaban concentrations (r = –0.44, 
P = 0.01) (FIGURE 2B) and with high rivaroxaban 
concentrations (r = –0.91, P <0.001) (FIGURE 2C). 
The group with low rivaroxaban concentrations 
had 57% longer CLT compared with the high ri‑
varoxaban group (mean [SD], 107.9 [19.7] min vs 
70.7 [19.5] min; P <0.001) (FIGURE 2D).
Both CLT and Ks were correlated with time 
from the last rivaroxaban administration (r = 0.61, 
P = 0.01 and r = –0.59, P = 0.01, respectively).
Follow ‑up The follow ‑up ranged from 5 to 61 
months (median, 32 months) and comprised 
329.7 patient ‑years. None of the patients was 
lost to follow ‑up. We observed 12 major bleeds 
or clinically relevant nonmajor bleeding events 
(9.1% and 3.6% per year, respectively), including 
7 patients with gastrointestinal bleeding (58% 
with STATISTICA 13.0 software (StatSoft Inc., 
Tulsa, Oklahoma, United States).
RESULTS Patient characteristics A total of 132 
patients (62 men and 70 women) were includ‑
ed into the analysis (TABLE 1). There were 48 pa‑
tients (36.4%) with isolated DVT, 30 patients 
(22.7%) with PE alone, 49 patients (37.1%) with 
PE combined with DVT, and 5 patients (3.8%) 
TABLE 1 Characteristics of patients with venous thromboembolism by plasma 
rivaroxaban levels at enrollment
Variable Low rivaroxaban 
levels (n = 67)
High rivaroxaban 
levels (n = 65)
P value
Age, y, median (IQR) 42 (19) 41 (18) 0.83
Male sex, n (%) 29 (43.28) 33 (50.77) 0.39
BMI, kg/m2, median (IQR) 27.78 (8.22) 26.40 (5.51) 0.14
Cigarette smoking, n (%) 16 (23.88) 13 (20) 0.59
Oral contraceptivesa, n (%) 14 (36.84) 12 (37.5) 0.84
Family history of VTE, n (%) 21 (31.34) 17 (26.15) 0.51
Varices, n (%) 25 (37.31) 21 (32.31) 0.55
Unprovoked VTE, n (%) 35 (56.92) 37 (52.24) 0.59
Obesity, n (%) 15 (23.08) 25 (37.31) 0.08
Comorbidities, n (%)
Arterial hypertension 22 (32.84) 19 (29.23) 0.65
Diabetes mellitus 2 (2.99) 3 (4.62) 0.62
Coronary heart disease 3 (4.48) 2 (3.08) 0.67
Hypercholesterolemia 33 (49.25) 42 (64.62) 0.07
Hypertriglyceridemia 10 (14.93) 11 (16.92) 0.75
Laboratory investigations
Hemoglobin, g/dl, median (IQR) 14 (1.7) 14.2 (2.0) 0.53
Platelets, 103/μl, median (IQR) 226 (69) 246 (74) 0.05
Creatinine, μmol/l, median (IQR) 69 (17) 72 (21) 0.35
Glucose, mmol/l, median (IQR) 5.2 (0.7) 5.2 (0.8) 0.74
Triglycerides, mmol/l, median (IQR) 1.04 (0.77) 1.17 (0.7) 0.38
TC, mmol/l, median (IQR) 5.08 (1.32) 5.07 (1.25) 0.9
HDL ‑C, mmol/l, median (IQR) 1.52 (0.56) 1.45 (0.51) 0.16
LDL ‑C, mmol/l, median (IQR) 3.25 (1.3) 3.35 (1.2) 0.58
hs ‑CRP, mg/l, median (IQR) 1.48 (2.81) 1.32 (2.9) 0.68
D ‑dimer, ng/ml, median (IQR) 270 (206) 216 (152) 0.04
Fibrinogen, g/l, median (IQR) 3 (1.26) 3.11 (0.97) 0.96
Ks, 10–9 cm2, median (IQR) 6.37 (1.6) 9.04 (2) 0.01
CLT, min, mean (SD) 107.8 (19.7) 70.66 (19.5) 0.01
Thrombophilia, n (%)
Factor V Leiden 19 (28.36) 20 (30.77) 0.76
Prothrombin 20210A mutation 7 (10.45) 4 (6.15) 0.27
Protein C deficiency 1 (1.54) 2 (2.99) 0.58
Protein S deficiency 2 (3.08) 4 (5.97) 0.43
Antithrombin deficiency 1 (1.54) 2 (2.99) 0.58
Hyperhomocysteinemia 16 (23.88) 11 (16.92) 0.32
a Women only
Abbreviations: BMI, body mass index; CLT, clot lysis time; HDL ‑C, high ‑density 
lipoprotein cholesterol; hs ‑CRP, high ‑sensitivity C ‑reactive protein; IQR, interquartile 
range; Ks, clot permeability; LDL ‑C, low ‑density lipoprotein cholesterol; PE, pulmonary 
embolism; TC, total cholesterol; VTE, venous thromboembolism
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(TABLE 2). Patients with a recurrent VTE episode 
presented with lower mean Ks (–26.7%) and pro‑
longed CLT (+20.8%) at enrollment (TABLE 2).
The multivariable logistic regression model 
with adjustment for potential confounders such 
as age, sex, BMI, fibrinogen, rivaroxaban concen‑
tration, and unprovoked / provoked VTE status, 
showed that Ks (OR, 0.23; 95% CI, 0.06–0.94) 
was the only predictor of recurrent VTE in our 
cohort (TABLE 3). No predictors of bleeding were 
identified in our study group.
DISCUSSION To our knowledge, this cohort 
study is the first to assess fibrin clot properties 
as potential predictors of VTE recurrences and 
bleeding episodes in patients with VTE treated 
with DOACs. Our study demonstrates that pa‑
tients on rivaroxaban who form more compact 
fibrin networks, which is reflected by lower plas‑
ma Ks with impaired clot lysability as evidenced 
by prolonged CLT, are more prone to VTE recur‑
rence. Contrary to our expectations, we failed 
to observe any association between clot prop‑
erties on rivaroxaban and major bleeds or clini‑
cally relevant nonmajor bleeding during follow‑
‑up. Although there were strong correlations be‑
tween rivaroxaban levels, assessed using an anti‑
‑Xa assay, and clot features, we found that clot 
of all events). There was no difference between 
the group with high rivaroxaban concentrations 
and the group with low rivaroxaban concentra‑
tions in this regard (n = 6; 9.23% vs n = 6; 8.96%, 
respectively; P = 0.96). Among individuals who 
experienced significant bleeding during follow‑
‑up, 6 patients had a history of proximal isolated 
DVT and 6 experienced PE. Acetylsalicylic acid or 
statins were used at a similar rate among patients 
with or without bleedings (P = 0.52 and P = 0.45, 
respectively) (TABLE 2). There was no difference in 
Ks and CLT values between patients who experi‑
enced relevant bleeding or not (TABLE 2).
In the multivariable logistic regression mod‑
el adjusted for potential confounders (age, sex, 
BMI, unprovoked VTE, fibrinogen and rivaroxa‑
ban concentrations), neither Ks nor CLT predict‑
ed bleeding on rivaroxaban (OR, 0.85; 95% CI, 
0.4–1.8; P = 0.66 and OR, 0.98; 95% CI, 0.92–1.04; 
P = 0.58, respectively).
Recurrent VTE occurred in 9 patients (6.82%; 
2.7% per year), including 5 patients with DVT 
alone and 4 with PE. All those patients belonged 
to the group with high rivaroxaban concentra‑
tions (n = 9, 13.43%). Patients who had recurrent 
VTE had unprovoked VTE more often as com‑
pared with those free of recurrent episodes (n = 
8, 88.9%, vs n = 64, 52%, respectively; P = 0.03) 
FIGURE 1 Correlation between plasma rivaroxaban concentrations and clot permeability (Ks) in the whole group (A), in the low rivaroxaban group (B), 
and in the high rivaroxaban group (C); comparison of Ks in the high and the low rivaroxaban groups (D). Horizontal lines represent medians in each 
group.
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coagulation and fibrinolysis proteins,and post‑
translational modifications of fibrinogen.14,17 Fi‑
brin, the product of thrombin ‑mediated proteo‑
lytic cleavage of fibrinogen, provides biophysi‑
cal and biochemical support to blood clots.34 It 
is well known that elevated thrombin concentra‑
tions lead to formation of denser fibrin networks 
composed of thinner fibers that are relatively re‑
sistant to plasmin ‑mediated lysis.34
Direct inhibition of factor X induced by riva‑
roxaban and consequently decreased thrombin 
formation could favorably affect fibrin clot struc‑
ture and susceptibility to lysis, as demonstrated 
previously.19,35,36 We confirmed that the rivarox‑
aban concentration is strongly positively corre‑
lated with Ks and negatively with CLT. Important‑
ly, our findings suggest that the modulation of fi‑
brin clot properties by rivaroxaban cannot sup‑
press the association of Ks with recurrent VTE, 
as demonstrated previously among patients with 
VTE who stopped anticoagulation.16,26 Even if ri‑
varoxaban improved clot properties, less favor‑
able plasma clot characteristics on rivaroxaban, 
in particular compact clot networks, remained 
the risk factor for recurrent VTE. It might be 
permeability, being a key measure of clot net‑
work density, remains a significant independent 
predictor of recurrent VTE during anticoagula‑
tion, also after adjustment for confounding fac‑
tors, that is, age, sex, BMI, fibrinogen, rivaroxa‑
ban concentration, and unprovoked / provoked 
VTE status. Our findings suggest that there is 
a relationship between fibrin clot characteris‑
tics and subsequent thromboembolic events in 
patients with VTE receiving rivaroxaban, which 
expands the current knowledge about the role 
of fibrin clot structure in thromboembolism in 
various disease states.
The incidence of thromboembolic and bleed‑
ing episodes in our cohort during follow ‑up cor‑
responds to that reported in previous studies.32 
The baseline characteristics of the patients, in‑
cluding the prevalence of VTE risk factors, were 
similar to other studies of VTE.26,33 It is likely that 
the present findings could refer to most patients 
with VTE treated with rivaroxaban.
According to available literature, several geneti‑
cally determined and predominantly environmen‑
tal factors that alter fibrin clot properties should 
be considered, including those affecting levels of 
FIGURE 2 Correlation between plasma rivaroxaban concentration and clot lysis time (CLT) in the whole group (A), in the low rivaroxaban group (B), 
and in the high rivaroxaban group (C); comparison of CLT in the high and the low rivaroxaban groups (D). Horizontal lines represent medians in each 
group.
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TABLE 2 Baseline characteristics of patients according to recurrent venous thromboembolism and clinically relevant bleeding during follow ‑up while 
on rivaroxaban
Variable Patients with VTE 
recurrence (n = 9)
Patients without VTE 
recurrence (n = 123)
Patients with 
bleeding (n = 12)
Patients without 
bleeding (n = 120)
Age, y, median (IQR) 43 (12) 41 (19) 41.5 (18) 41.5 (18.5)
Male sex, n (%) 4 (44.4) 58 (47.2) 7 (58.3) 55 (45.8)
BMI, kg/m2, median (IQR) 29.1 (6.4) 26.8 (7.6) 27.3 (7.7) 26.9 (7.1)
Cigarette smoking, n (%) 3 (33.3) 26 (21.1) 2 (16.7) 27 (22.5)
Oral contraceptivesa, n (%) 1 (20) 25 (38.5) 1 (20) 25 (38.5)
Family history of VTE, n (%) 4 (44.4) 34 (27.6) 4 (33.3) 34 (28.3)
Varices, n (%) 3 (33.3) 43 (35) 2 (16.7) 44 (36.7)
Unprovoked VTE, n (%) 8 (88.9) 64 (52)b 3 (25) 69 (57.5)b
Obesity, n (%) 4 (44.4) 36 (29.3) 4 (33.3) 36 (30)
Use of ASA, n (%) 0 (0) 4 (3.25) 0 (0) 4 (3.33)
Use of statins, n (%) 0 (0) 21 (17.1) 1 (8.33) 20 (16.7)
Comorbidities, n (%)
Arterial hypertension 3 (33.3) 38 (30.9) 2 (16.7) 39 (32.5)
Diabetes mellitus 1 (11.1) 4 (3.25) 1 (8.3) 4 (3.3)
Coronary heart disease 1 (11.1) 4 (3.25) 0 (0) 5 (4.2)
Hypercholesterolemia 3 (33.3) 72 (58.5) 6 (50) 69 (57.5)
Hypertriglyceridemia 0 (0) 21 (17.1) 0 (0) 21 (17.5)
Laboratory investigations
Hemoglobin, g/dl, mean (SD) 14.3 (2.7) 14.1 (1.8) 13.6 (2.2) 14.05 (1.6)
Platelets, 103/μl, median (IQR) 209 (66) 242 (72) 222 (74.5) 242 (74)
Creatinine, μmol/l, median (IQR) 81 (17.8) 72.9 (14.9) 72.5 (22.5) 69 (19)
Glucose, mmol/l, median (IQR) 5 (0.2) 5.2 (0.8) 5.35 (1.25) 5.2 (0.7)
Triglycerides, mmol/l, median (IQR) 1.24 (0.66) 1.05 (0.77) 1.01 (0.57) 1.12 (0.77)
TC, mmol/l, median (IQR) 5.06 (0.9) 5.08 (1.29) 5.11 (1.62) 5.08 (1.27)
HDL ‑C, mmol/l, median (IQR) 1.46 (0.35) 1.47 (0.54) 1.59 (0.75) 1.46 (0.51)
LDL ‑C, mmol/l, median (IQR) 3.41 (1.5) 3.29 (1.26) 3.42 (1.19) 3.28 (1.27)
hs ‑CRP, mg/l, median (IQR) 0.94 (1.71) 1.44 (2.87) 1.28 (1.42) 1.43 (2.84)
D ‑dimer, ng/ml, median (IQR) 270 (144) 236 (183) 269 (170.5) 234.5 (184.5)
Fibrinogen, g/l, median (IQR) 3.17 (0.57) 3.03 (1.19) 2.65 (0.59) 3.13 (1.23)b
Ks, 10–9 cm2, median (IQR) 5.5 (0.8) 7.8 (2.5)b 7.1 (2.9) 7.85 (1.55)
CLT, minutes, median (IQR) 106.7 (24.5) 88.3 (26.8)b 89 (38.5) 96.5 (42)
Thrombophilia, n (%)
Factor V Leiden 3 (33.3) 36 (29.3) 4 (33.3) 35 (29.2)
Prothrombin 20210A mutation 0 (0) 11 (8.9) 1 (8.3) 10 (8.3)
Protein C deficiency 0 (0) 3 (2.4) 0 (0) 3 (2.5)
Protein S deficiency 1 (11.1) 5 (4.1) 0 (0) 6 (5.0)
Antithrombin deficiency 0 (0) 3 (2.4) 1 (8.3) 2 (1.7)
Hyperhomocysteinemia 3 (33.3) 24 (19.5) 3 (25) 24 (20)
a Women only;   b P value <0.05
Abbreviations: ASA, acetylsalicylic acid; others, see TABLE 1
TABLE 3 Multivariable logistic regression model for venous thromboembolism recurrences
Variable OR (95% CI)
Unadjusted P value Adjusteda P value
Ks 0.14 (0.04–0.52) 0.04 0.18 (0.04–0.78) 0.02
CLT 0.96 (0.92–1.00) 0.92 0.96 (0.91–1.00) 0.17
a Adjusted for age, sex, BMI, unprovoked VTE, fibrinogen and rivaroxaban concentration
Abbreviations: OR, odds ratio; others, see TABLE 1
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speculated that the measurement of clot perme‑
ability during treatment with other oral antico‑
agulants might also have a predictive value. This 
hypothesis of potential clinical relevance merits 
further investigation.
The current study indicates that clot proper‑
ties determined on rivaroxaban have no predictive 
value for relevant bleedings. Given varying dura‑
tion of the time intervals between the last dose 
of rivaroxaban and blood draw as well as large 
interindividual differences in the drug’s concen‑
tration, a single measurement of Ks or CLT per‑
formed on anticoagulation is not helpful in iden‑
tifying patients at risk for anticoagulation ‑related 
bleeding episodes. The question remains whether 
the result would be different if the measurement 
of Ks or CLT was done off anticoagulation. It re‑
mains to be established whether Ks measured in 
patients with VTE off anticoagulation could be 
of similar significance.
Our study has several limitations. Our cohort 
was small and the number of the outcomes re‑
corded was also low as expected given the efficacy 
and safety of rivaroxaban. Therefore, all outcome‑
‑related findings should be interpreted with cau‑
tion. Nevertheless, the association of Ks with re‑
current VTE observed in VTE patients on rivar‑
oxaban is interesting and this finding generates 
a new hypothesis to be tested on large cohorts 
in the future. Our findings cannot be easily ex‑
trapolated to elderly patients or patients with 
malignancies because they were excluded from 
the study. We cannot eliminate the possibility 
that some of the VTE recurrences were related to 
poor compliance and interruptions in anticoagula‑
tion, since the rivaroxaban concentration was not 
measured at the time of VTE diagnosis. Finally, it 
is unclear whether clot phenotype has its predic‑
tive value in patients with VTE on warfarin, al‑
though there is evidence from patients with atri‑
al fibrillation that might support this concept.37
To conclude, we demonstrated that clot den‑
sity is associated with an increased risk of VTE 
recurrences during treatment with rivaroxaban. 
None of the analyzed parameters was found to be 
predictive of bleeding episodes in anticoagulat‑
ed patients with VTE. This study might suggest 
that clot permeability may be useful in identify‑
ing a subset of patients with VTE at high risk of 
thromboembolic episodes despite therapy with 
rivaroxaban, who could have been candidates for 
other medications or dosing regimens in long‑
‑term secondary prevention. Future larger stud‑
ies are warranted to validate this hypothesis.
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